Health Care • Medicinal Chemicals and Botanical Products
$3.36 ▲ +0.01
(+0.30%)
MKT CAP: $1.24B • VOL: 666.4K
52W L $2 52W H $4
CRON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $146.6M | $117.6M | $87.2M |
| YoY Revenue Growth % | +24.6% | +34.8% | — |
| Gross Profit | $62.8M | $25.2M | — |
| Gross Margin % | 42.8% | 21.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.4M | -$76.5M | -$84.8M |
| Operating Margin % | -11.9% | -65.1% | -80.0% |
| Net Income (GAAP) | -$2.9M | $40.0M | -$73.9M |
| EBITDA (Normalized) | $3.2M | -$66.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $25.9M | $18.8M | -$42.8M |
| Capital Expenditures (CapEx) | $25.7M | $12.4M | — |
| Free Cash Flow (FCF) | $149.0K | $6.4M | -$42.8M |
| FCF Margin % | 0.1% | 5.5% | -49.1% |
| Return on Invested Capital (ROIC %) | -4.5% | -29.5% | — |
| Cash & Short-Term Equivalents | $791.8M | $858.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.09B | $1.06B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRON.